The FDA granted the first pediatric indication for an implantable cardiac monitor. The Linq II can be used in pediatric patients over the age of 2 for up to 4.5 years of long-term, continuous monitoring. 

Comparison between transcatheter edge-to-edge repair (TEER) devices found Pascal was non-inferior compared with MitraClip in the CLASP IID pivotal trial.

The UNIVERSAL Trial, one of the largest multicenter randomized trials comparing ultrasound with fluoroscopic guidance vs. fluoroscopic guidance alone, found there was no reduction in major vascular access complications. 

This is the fourth device in Medtronic's Evolut TAVR platform. The self-expanding valve gained FDA approval in 2021 for the treatment of high- and low-risk patients presenting with symptomatic severe aortic stenosis.

“The United States is essentially inventing the technology and then the rest of the world is figuring out how to use it better,” he said.

Results from the Medtronic SYMPLICITY HTN-3 trial long-term results and the pivotal RADIANCE II trial for the Recor ultrasound renal denervation system lowered blood pressure effectively in drug-resistant patients.

The PROTECTED TAVR results presented at TCT 2022 resulted in a mix of reactions. For some cardiologists, the slight reduction in the risk of a disabling stroke after TAVR is a positive result. For others, it was simply not enough. 

A 31-year-old patient developed acute myocarditis shortly after the onset of monkeypox symptoms. The team that treated him shared their story in a new case study.

Though removal of the affected CIED is typically the smartest treatment option—and one supported by specialty groups all over the world—a majority of patients keep living with the device, often resulting in hospitalization or even death.

After experts from one institution evaluated 500 portable chest x-rays completed during the summer of 2021, it was revealed that 46.2% of the images obtained were problematic, requiring the imaging to be repeated. 

UnitedHealth Group can move ahead with its planned $13 billion acquisition of Change Healthcare after a district court shot down the Department of Justice’s attempt to block the transaction.